# **Key Information Document**



# Purpose

This document provides you with key information about this investment product. It is not marketing material. The information is required by law to help you understand the nature, risks, costs, potential gains and losses of this product and to help you compare it with other products.

# Global X China Biotech UCITS ETF a sub-fund of Global X ETFs II ICAV USD Accumulating (IE0004LIBFM2)

Manufacturer: Global X Management Company (Europe) Limited, part of the Global X group of companies.

The Central Bank of Ireland is responsible for supervising Global X Management Company (Europe) Limited in relation to this Key Information Document.

This PRIIP is authorised in Ireland.

Global X Management Company (Europe) Limited is authorised in Ireland and regulated by the Central Bank of Ireland. For more information on this product, please visit <u>www.globalxetfs.eu</u>, email <u>europe@globalxetfs.com</u> or call : +1-852-3555-5833.

This document was produced on 31 January 2024.

## What is this product?

Type:

This product is UCITS fund.

#### Term:

This is an Open Ended Fund.

#### **Objectives:**

The Fund's investment objective is to provide investment results that, closely correspond, before fees and expenses to the performance of the Solactive China Biotech v2 USD Index Net Total Return (the "Index"). The Fund will aim to achieve its investment objective by attempting to replicate the performance of the Index by investing primarily in a portfolio of equity securities that as far as possible and practicable consists of the constituent stocks of the Index.

For Accumulating Shares, income will be automatically reinvested in the Fund and reflected in the NAV per share.

The Fund is open for subscriptions and redemptions on each Dealing Day. Dealing day means a day on which the Hong Kong Stock Exchange is open for normal business or such Business Day(s) as the Directors may from time to time determine for dealings in the Fund (and notify in advance to Shareholders). The dealing cut-off time for the Fund is 4:00pm (Dublin time) on each business day prior to the relevant dealing day. Business day means a weekday other than the Friday before Easter, Christmas Day and New Year's day.

For more information about the investment policy and strategy of the Fund, please refer to the sections entitled "Investment Objective" and "Investment Policy" of the Fund's Supplement. Fund documents including the Prospectus, Supplement and the latest annual and half-yearly reports are available free of charge in English. These can be found, along with other information, such as share prices and classes, on the Fund's website at www.globalxetfs.eu.

The depositary is Brown Brothers Harriman Trustee Services (Ireland) Limited.

This document describes a sub-fund of the UCITS. The Prospectus and periodic reports are prepared in respect of the entire UCITS. The assets and liabilities of each sub-fund of the UCITS are segregated by law, and so the assets of one sub-fund cannot be used to discharge the liabilities of another sub-fund.

#### Intended retail investor:

This product is intended for investors who are prepared to take on a relatively high level of risk of loss to their original capital in order to get a higher potential return, and who plan to stay invested for at least 5 years. It is designed to form part of a portfolio of investments.

# What are the risks and what could I get in return?

#### **Risk Indicator**



The risk indicator assumes you keep the product for 5 years.

The actual risk can vary significantly if you cash in at an early stage and you may get back less.

The summary risk indicator is a guide to the level of risk of this product compared to other products. It shows how likely it is that the product will lose money because of movements in the markets or because we are not able to pay you. We have classified this product as 5 out of 7, which is a medium-high risk class. This rates the potential losses from future performance at a medium-high level, and poor market conditions will likely impact the ability for you to receive a positive return on your investment.

This product does not include any protection from future market performance so you could lose some or all of your investment. If we are not able to pay you what is owed, you could lose your entire investment. For other risks materially relevant to the product which are not taken into account in the summary risk indicator, please read the Prospectus and Supplement available at www.globalxetfs.eu

#### Performance scenarios

The figures shown include all the costs of the product itself, but may not include all the costs that you pay to your advisor or distributor / and includes the costs of your advisor or distributor. The figures do not take into account your personal tax situation, which may also affect how much you get back.

The unfavourable, moderate, and favourable scenarios shown are illustrations using the worst, average, and best performance of Global X China Biotech UCITS ETF over the last 5 years.

The stress scenario shows what you might get back in extreme market circumstances.

What you will get from this product depends on future market performance. Market developments in the future cannot be accurately predicted. The scenarios shown are only an indication of some of the possible outcomes based on recent returns. Actual returns could be lower.

Recommended Holding Period: 5 years Investment: USD 10,000					
Stress	What you might get back after costs	2,570 USD	1,520 USD		
	Average return each year	-74.25%	-31.41%		
Unfavourable <sup>1</sup>	What you might get back after costs	4,810 USD	4,160 USD		
	Average return each year	-51.90%	-16.08%		
Moderate <sup>2</sup>	What you might get back after costs	11,470 USD	24,430 USD		
	Average return each year	14.74%	19.56%		
Favourable <sup>3</sup>	What you might get back after costs	23,490 USD	43,770 USD		
	Average return each year	134.87%	34.35%		

<sup>1</sup> This type of scenario occurred for an investment between June 2021 and December 2023.

<sup>2</sup> This type of scenario occurred for an investment between June 2015 and June 2020.

<sup>3</sup> This type of scenario occurred for an investment between May 2016 and May 2021.

# What happens if Global X Management Company (Europe) Limited, part of the Global X group of companies is unable to pay out?

You may face a financial loss should the manufacturer or depositary/custodian, Brown Brothers Harriman Trustee Services (Ireland) Limited, default on their obligations.

There is no compensation or guarantee scheme in place which may offset, all or any of, this loss.

## What are the costs?

The person advising on or selling you this product may charge you other costs. If so, this person will provide you with information about these costs and how they affect your investment.

#### Costs over time

The tables show the amounts that are taken from your investment to cover different types of costs. These amounts depend on how much you invest, how long you hold the product and how well the product does. The amounts shown here are illustrations based on an example investment amount and different possible investment periods.

We have assumed, in the first year you would get back the amount that you invested (0 % annual return). For the other holding period, we have assumed the fund performs as shown in the moderate scenario and the investment is USD 10,000.

Investment: USD 10,000	lf you exit after 1 year	lf you exit after 5 years
Total costs	104 USD	1,144 USD
Annual cost impact (*)	1.0%	1.1%

(\*) This illustrates how costs reduce your return each year over the holding period. For example it shows that if you exit at the recommended holding period your average return per year is projected to be 20.7% before costs and 19.6% after costs.

#### Global X China Biotech UCITS ETF, a sub-fund of Global X ETFs II ICAV - USD Accumulating (IE0004LIBFM2)

Composition of costs

One-off costs upon entry or exit		lf you exit after 1 year
Entry costs	None * * Secondary market investors (Investors dealing on a stock exchange) may pay fees charged by their stock brokers. Such charges, if any, can be obtained from stock brokers. Authorised participants dealing directly with the Fund will pay related transaction costs related to their subscriptions and redemptions.	0 USD
Exit costs	None * * Secondary market investors (Investors dealing on a stock exchange) may pay fees charged by their stock brokers. Such charges, if any, can be obtained from stock brokers. Authorised participants dealing directly with the Fund will pay related transaction costs related to their subscriptions and redemptions.	0 USD
Ongoing costs taken each year		lf you exit after 1 year
Management fees and other administrative or operating costs	0.7% of the value of your investment per year. This is an estimate of the costs incurred when we buy and sell the underlying investments for the product. The actual amount will vary depending on how much we buy and sell.	68 USD
administrative or operating	incurred when we buy and sell the underlying investments for the product. The	68 USD 36 USD
administrative or operating costs	<ul> <li>incurred when we buy and sell the underlying investments for the product. The actual amount will vary depending on how much we buy and sell.</li> <li>0.4% of the value of your investment per year. This is an estimate of the costs incurred when we buy and sell the underlying investments for the product. The actual amount will vary depending on how much we buy and sell.</li> </ul>	

## How long should I hold it and can I take money out early?

#### Recommended holding period: 5 years

This product has no required minimum holding period but is designed for long term investment; you should be prepared to stay invested for at least 5 years. The 5 years has been calculated to be in line with the time frame which the Product may need in order to achieve its investment objectives. You may sell your shares in the product, without penalty, on any day on which the banks are normally open for business in Ireland.

The value of your investments may go down as well as up irrespective of the period you are holding your investments, depending on such factors as the performance of the Fund, movements in stock and bond prices, and conditions in financial markets generally. Please contact your broker, financial adviser or distributor for information on any costs and charges relating to the sale of the shares.

### How can I complain?

If you have any complaints about the product, the conduct of the manufacturer or the person advising on the product, complaints can be lodged free of charge via the following methods:

i. Phone: +44 (0)20 4529 2551

ii. E-mail: complaints@globalxetfs.com

iii. Mail: 10 Earlsfort Terrace, Dublin 2, Ireland

iv. Online: www.globalxetfs.eu/

You also have the right to refer the relevant complaint to the Financial Services and Pensions Ombudsman after following the Fund's complaints process if you are still not satisfied with the response received. Further information on the complaints policy relating to the Fund is available from <a href="http://www.globalxetfs.eu">www.globalxetfs.eu</a>.

## Other relevant information

We are required to provide you with further documentation, such as the product's latest prospectus, past performance annual and semi-annual reports. These documents and other product information are available online at <a href="https://globalxetfs.eu/priips-performance/">https://globalxetfs.eu/priips-performance/</a>.

To view the fund's historical performance and previous scenarios, please visit: <u>www.globalxetfs.eu</u>. Data on past performance is available for up to a maximum of 10 years.

The representative in Switzerland is 1741 Fund Solutions Limited, Burggraben 16, CH-9000 St. Gallen. Swiss Paying Agent in Switzerland is Tellco Limited, Bahnhofstrasse4, 6430 Schwyz, Switzerland. The Prospectus, Key Information Document, Instrument as well as the annual and semi-annual reports may be obtained free of charge from the representative. In respect of the units distributed in and from Switzerland, the place of performance and jurisdiction is the registered office of the Representative.